|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nonalcoholic steatohepatitis-associated hepatocellular carcinoma:Our case series and literature review显示文摘Recently,nonalcoholic steatohepatitis(NASH) has been considered to be another cause of liver cirrhosis and hepatocellular carcinoma(HCC).The natural history and prognosis of NASH are controversial.Accordingly,we assessed the clinicopathological features of NASH-associated HCC in our experience and reviewed the literature of NASH-associated HCC.We experienced 11 patients with NASH-associated HCC(6 male,5 female;mean age 73.8 ± 4.9 years) who received curative treatments.Most(91%) patients had been diagnosed with obesity,diabetes,hypertension,or dyslipidemia.Seven patients(64%) also had a non-cirrhotic liver.The recurrence-free survival rates at 1,3 and 5 years were 72%,60%,and 60%.We also summarized and reviewed 94 cases of NASH-associated HCC which were reported in the literature(64 male;mean age 66 years).The majority of patients(68%) were obese,66% of patients had diabetes,and 24% had dyslipidemia.Furthermore,26% of the HCCs arose from the non-cirrhotic liver.In conclusion,patients with non-cirrhotic NASH may be a high-risk group for HCC,and regular surveillance for HCC is necessary in non-cirrhotic NASH patients as well as cirrhotic patients. | Yoshitaka Takuma Kazuhiro Nouso | 2010 | World Journal of Gastroenterology2010，16，12： | 17 |
| 2 | Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer显示文摘 | Hideaki Kinugasa Kazuhiro Nouso Koji Miyahara Yuki Morimoto Chihiro Dohi Koichiro Tsutsumi Hironari Kato Takehiro Matsubara Hiroyuki Okada Kazuhide Yamamoto | 2015 | Cancer2015，，13： | 4 |
| 3 | Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age显示文摘The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma(HCC).After development of sorafenib and its introduction as a therapeutic agent used in the clinic,several critical questions have been raised.Clinical parameters and biomarkers predicting sorafenib efficacy are the most important issues that need to be elucidated.Although it is difficult to know the responders in advance using conventional characteristics of patients,there are specific serum cytokines and/or gene amplification in tumor tissues that have been reported to predict efficacy of sorafenib.Risk and benefits of continuation of sorafenib beyond radiological progression is another issue to consider because no other standard therapy for advanced HCC as yet exists.In addition,effectiveness of the expanded application of sorafenib is still controversial,although a few studies have shed some light on combinational treatment with sorafenib for intermediate-stage HCC.Recently,over 50 relevant drugs have been developed and are currently under investigation.The efficacy of some of these drugs has been extensively examined,but none have demonstrated any superiority over sorafenib,so far.However,there are several drugs that have shown efficacy for treatment after sorafenib failure,and these are proceeding to further studies.To address these issues and questions,we have done extensive literature review and summarize the most current status of therapeutic application of sorafenib. | Koji Miyahara Kazuhiro Nouso Kazuhide Yamamoto | 2014 | World Journal of Gastroenterology2014，20，15： | 3 |
| 4 | Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development显示文摘AIM: To investigate factors that accurately predict hepatocellular carcinoma(HCC) development after antiviral therapy in chronic hepatitis C(CHC) patients. METHODS: CHC patients who received pegylated interferon and ribavirin were enrolled in this cohort study that investigated the ability of alpha-fetoprotein(AFP) to predict HCC development after interferon(IFN) therapy. RESULTS: Of 1255 patients enrolled, 665 developed sustained virological response(SVR) during mean follow-up period of 5.4 years. HCC was occurred in 89 patients, and 20 SVR patients were included. Proportional hazard models showed that HCC occurred in SVR patients showing AFP ≥ 5 ng/m L before therapy and in non-SVR patients showing AFP ≥ 5 ng/m L before and 1 year after therapy besides older age, and low platelet counts. SVR patients showing AFP ≥ 5 ng/m L before therapy and no decrease in AFP to < 5 ng/m L 1 year after therapy had significantly higher HCC incidence than non-SVR patients showing AFP ≥ 5 ng/m L before therapy and decreased AFP(P = 0.043). AFP ≥ 5 ng/m L before therapy was significantly associated with low platelet counts and high values of alanine aminotransferase(ALT) in stepwise logistic regression analysis. After age, gender, platelet count, and ALT was matched by propensity score, significantly lower HCC incidence was shown in SVR patients showing AFP < 5 ng/m L before therapy than in those showing AFP ≥ 5 ng/m L.CONCLUSION: The criteria of AFP < 5 ng/m L before and 1 year after IFN therapy is a benefical predictor for HCC development in CHC patients. | Yasuto Takeuchi Fusao Ikeda Toshiya Osawa Yasuyuki Araki Kouichi Takaguchi Youichi Morimoto Noriaki Hashimoto Kousaku Sakaguchi Tatsuro Sakata Masaharu Ando Yasuhiro Makino Shuji Matsumura Hiroki Takayama Hiroyuki Seki Shintarou Nanba Yuki Moritou Tetsuya Yasunaka Hideki Ohnishi Akinobu Takaki Kazuhiro Nouso Yoshiaki Iwasaki Kazuhide Yamamoto | 2015 | World Journal of Hepatology2015，7，19： | 3 |
| 5 | Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma显示文摘 | Hideaki Kinugasa Kazuhiro Nouso Yasuto Takeuchi Tetsuya Yasunaka Hideki Onishi Shin-ichiro Nakamura Hidenori Shiraha Kenji Kuwaki Hiroaki Hagihara Fusao Ikeda Yasuhiro Miyake Akinobu Takaki Kazuhide Yamamoto | 2012 | Journal of Gastroenterology2012，，4： | 2 |
| 6 | Cellular distribution of telornerase reverse transcriptase in human hepatocellular carci- norna显示文摘 | Onishi T Nouso K Higashi T | 2003 | J Gastroenterol Hepatol2003，18，10： | 1 |
| 7 | Risk factors for localand distant recurrence of hepatocellular carcinomas after local abla-tion therapies显示文摘 | Nouso K Matsumoto E Kobayashi Y | 2008 | J Gastroenterol Hepatol2008，23，3： | 1 |
| 8 | Potential of adenovirus‐mediated REIC / Dkk ‐3 gene therapy for use in the treatment of pancreatic cancer显示文摘 | Daisuke Uchida Hidenori Shiraha Hironari Kato Teruya Nagahara Masaya Iwamuro Junro Kataoka Shigeru Horiguchi Masami Watanabe Akinobu Takaki Kazuhiro Nouso Yasutomo Nasu Takahito Yagi Hiromi Kumon Kazuhide Yamamoto | 2014 | J Gastroenterol Hepatol2014，，5： | 1 |
| 9 | Expression of membrane cofactor protein ( MCP, CD46) in human liver diseases显示文摘 | Kinugasa N Higashi T Nouso K | 1999 | Br J Cancer1999，80，： | 1 |
| 10 | Telomerase reverse transcriptase gene amplification in hepatocellular carcinoma 显示文摘 | Takuma Y Nouso K Shiratori Y | 2004 | J Gastroenterol Hepatol2004，19，11： | 1 |
| 11 | Apoptosis and proliferation of human hepatocellular cmeinoma显示文摘 | Hino N Higashi T Nouso K | 1996 | Liver1996，16，2： | 1 |
| 12 | Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan 显示文摘 | Nouso K Miyahara K Uchida D | 2013 | Bri J Canc- er2013，109，： | 1 |
| 13 | Telomerase asa tool for the chfletential diagnosis of human hepatocellular carcinoma显示文摘 | Urabe Y Higashi T | 1996 | Cancer1996，78，2： | 1 |
| 14 | Stable expression of human cytochrome P4502E1 in mammalian cells: metablolic activation of and formation of adducts with cellular DNA显示文摘 | Nouso K Thorgeirsaon SS Battula N | 1992 | Cancer Rea1992，52，： | 1 |
| 15 | Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma显示文摘 | Fujiwara K Higashi T Nouso K | 2004 | J Gastroenterol Hepatol2004，19，10： | 1 |
| 16 | Expression of telomer- ase associated protein 1 and telomerase transcriptase in hepato- cellular carcinoma显示文摘 | Toshikuni N Nouso K Higashi T | 2000 | Br J Cancer2000，82，6： | 1 |
| 17 | Decreased expression of B7 costimu- latory molecules and major histocompatibility complex class-I in hu- man hepatocellular carcinoma 显示文摘 | Fujiwara K Higashi T Nouso K | 2004 | J Gastroenterol Hepatol2004，19，10： | 1 |
| 18 | Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size 显示文摘 | Nakamura S Nouso K Sakaguchi K | 2006 | Am J Gastroenterol2006，101，9： | 1 |
| 19 | Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure repair显示文摘 | Yumoto E Higashi T Nouso K | 2002 | J Gastroenterol Hepatol2002，17，3： | 1 |
| 20 | Altered expression of vascular endothelial growth factor,fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma显示文摘 | Uematsu S Higashi T Nouso K | 2005 | J Gastroenterol Hepatol2005，20，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员